Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 6.96 as of 2026-10-06T15:06:36.582Z.
Consensus retrieved: 2026-10-06T11:22:30.799Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:06:36.582Z.
Quote observation: 2026-10-06T14:53:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f5b5977bdf8e8744ccf3bd9773e74661520241b62ab886de63a55e038e5fa23
Forward PE Ratio (6.96) = Dated Quote Price ($17.75) / Consensus Forward EPS ($2.55)
FORWARD PE RATIO
6.96
SECTOR MEDIAN · HEALTHCARE
18.95
median of 162 covered companies
CURRENT VS SECTOR MEDIAN
-63.26%
vs the sector median at left
Fortress Biotech, Inc.
Market Cap
$139.73M
Forward PE Ratio
6.96
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Fortress Biotech, Inc. (FBIOP) | $139.73M | 6.96 |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | N/A |
| Nyxoah S.A. (NYXH)vs › | $142.60M | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.65M | N/A |
| LifeMD, Inc. (LFMD)vs › | $135.66M | N/A |
| Immuneering Corporation (IMRX)vs › | $145.39M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.68M | N/A |
| Freenome, Inc. (FRNM)vs › | $133.72M | N/A |
| Organigram Global Inc. (OGI)vs › | $132.67M | N/A |
Trailing P/E
6.6
reported TTM EPS
Forward P/E
7.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.55 implies -4.9% EPS decline vs the reported trailing $2.68.
At the dated quote price of $17.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.55 | $2.55 – $2.55 | 1 | 7.0x |
| 2027-12-31 | $-1.00 | $-1.00 – $-1.00 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
